MedPath

Asmacure Ltée

Asmacure Ltée logo
🇺🇸United States
Ownership
Private, Subsidiary
Established
2002-01-01
Employees
1
Market Cap
-
Website
http://www.asmacure.com

Clinical Trials

4

Active:0
Completed:3

Trial Phases

2 Phases

Phase 1:1
Phase 2:3

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials

Phase 2
3 (75.0%)
Phase 1
1 (25.0%)

Safety, Tolerability, and Clinical Activity of ASM-024 Administered to Patients With GOLD 2 or GOLD 3 Chronic Obstructive Pulmonary Disease (COPD)

Phase 2
Completed
Conditions
COPD
Interventions
Drug: Placebo
First Posted Date
2013-05-16
Last Posted Date
2014-12-16
Lead Sponsor
Asmacure Ltée
Target Recruit Count
14
Registration Number
NCT01855230
Locations
🇨🇦

Institut universitaire de cardiologie et de pneumologie de Québec, Quebec, Canada

Safety, Tolerability and Pharmacokinetics of ASM-024 Administered to Healthy Subjects and Subjects With Moderate Asthma

Phase 1
Terminated
Conditions
Asthma
Interventions
First Posted Date
2013-02-15
Last Posted Date
2015-02-10
Lead Sponsor
Asmacure Ltée
Target Recruit Count
55
Registration Number
NCT01793298
Locations
🇨🇦

PharmaNet, Québec, Quebec, Canada

🇨🇦

Institut universitaire de cardiologie et de pneumologie de Québec, Québec, Quebec, Canada

Safety, Tolerability and Clinical Activity of ASM-024 in Stable Moderate Asthma

Phase 2
Completed
Conditions
Asthma
Interventions
Drug: ASM-024 100 mg
Drug: Placebo
First Posted Date
2010-08-30
Last Posted Date
2012-03-15
Lead Sponsor
Asmacure Ltée
Target Recruit Count
20
Registration Number
NCT01190826
Locations
🇨🇦

McMaster University, Hamilton, Ontario, Canada

🇨🇦

Anapharm, Montreal, Quebec, Canada

🇨🇦

Centre de Recherche Institut universitaire de cardiologie et de pneumologie de Québec, Quebec, Canada

Safety, Tolerability and Clinical Activity of ASM-024 in Subjects With Mild Allergic Asthma

Phase 2
Completed
Conditions
Mild Allergic Asthma
Interventions
Drug: Placebo
First Posted Date
2010-03-25
Last Posted Date
2012-01-26
Lead Sponsor
Asmacure Ltée
Target Recruit Count
24
Registration Number
NCT01092403
Locations
🇨🇦

Mc Master University Health Sciences Center, Hamilton, Quebec, Canada

🇨🇦

Centre de Recherche - Institut universitaire de cardiologie et de pneumologie de Québec, Québec, Quebec, Canada

🇨🇦

University of Saskatechewan, Saskatoon, Saskatchewan, Canada

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.